Lipocine Shares Rise After Insider Buys $81,199 Stake Insider Higuchi bought $81,199 of Lipocine (LPCN) stock on Apr 7, 2026 (SEC Form 4; Investing.com), a modest buy that increases monitoring priority.

Lipocine Shares Rise After Insider Buys $81,199 Stake: Insider Higuchi bought $81,199 of Lipocine (LPCN) stock on Apr 7, 2026 (SEC Form 4; Investing.com), a modest buy that increases monitoring priority. 👈 Read full analysis #Lipocine #StockMarket #Investing #InsiderTrading #Finance

Lipocine Insider Buys $252,149 of Shares John W. Higuchi bought $252,149 of Lipocine (LPCN) shares on Apr 6, 2026 (Investing.com); Form 4 filed under SEC two-business-day rule — interpret as a single low-conviction signal.

Lipocine Insider Buys $252,149 of Shares: John W. Higuchi bought $252,149 of Lipocine (LPCN) shares on Apr 6, 2026 (Investing.com); Form 4 filed under SEC two-business-day rule — interpret as a single low-conviction signal. 👈 Read full analysis #Lipocine #InsiderBuying #Stocks #Investing #Finance

Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial Lipocine Inc.'s Phase 3 trial results for LPCN 1154 in postpartum depression reveal mixed efficacy and a well-tolerated safety profile among participants.

Lipocine’s LPCN 1154 Shows Mixed Results in Treating Postpartum Depression During Phase 3 Trial #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities Lipocine Inc. shared its financial results for 2025, showcasing significant pipeline developments for mental health and metabolic disorders, setting the stage for future progress.

Lipocine's 2025 Financial Report Highlights Pipeline Progress and Market Opportunities #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment Lipocine Inc. completes the last patient visit in the Phase 3 trial of LPCN 1154, an oral treatment for postpartum depression (PPD), showing positive safety results.

Lipocine's LPCN 1154 Marks Final Phase 3 Trial Visit for PPD Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression Lipocine has finished participant enrollment and dosing in its Phase 3 clinical trial for LPCN 1154, aimed at treating postpartum depression. Initial results are promising.

Lipocine Completes Phase 3 Trial Enrollment for LPCN 1154 Targeting Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review Lipocine Inc. announced the successful completion of an independent safety review for LPCN 1154 in a Phase 3 trial targeting postpartum depression, reinforcing confidence in its efficacy.

Lipocine's LPCN 1154 Shows Positive Results in PPD Phase 3 Trial Review #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment Lipocine Inc. has achieved 80% enrollment in its Phase 3 clinical trial for LPCN 1154, an innovative treatment for postpartum depression (PPD).

Lipocine Reaches Milestone in Phase 3 Study for Postpartum Depression Treatment #USA #Salt_Lake_City #Lipocine #LPCN_1154 #PPD_Treatment

Lipocine Reports Q3 2025 Financial Results and Clinical Updates Lipocine Inc. announces third quarter financial results for 2025 and updates on clinical trials, including LPCN 1154 for postpartum depression.

Lipocine Reports Q3 2025 Financial Results and Clinical Updates #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine Unveils Promising LPCN 2401 Data at ObesityWeek Conference Lipocine Inc. presents groundbreaking results for LPCN 2401 at ObesityWeek, showcasing significant improvements in body composition and liver health for individuals with obesity.

Lipocine Unveils Promising LPCN 2401 Data at ObesityWeek Conference #United_States #obesity #Salt_Lake_City #Lipocine #LPCN_2401

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression Lipocine Inc. shares an update on its Phase 3 trial of LPCN 1154 for postpartum depression, with promising enrollment and safety review plans.

Lipocine's LPCN 1154 Phase 3 Trial Progress in Treating Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine to Showcase Groundbreaking Research at H.C. Wainwright Conference Lipocine Inc. will present innovative drug development strategies at the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025.

Lipocine to Showcase Groundbreaking Research at H.C. Wainwright Conference #United_States #Salt_Lake_City #Lipocine #LPCN #Brexanolone

Lipocine's LPCN 2101 Accepted for Presentation at AES 2025 Conference in Atlanta Lipocine Inc. is set to present two significant abstracts on LPCN 2101 at the AES annual meeting in December 2025, focusing on epilepsy treatment.

Lipocine's LPCN 2101 Accepted for Presentation at AES 2025 Conference in Atlanta #United_States #Atlanta #Lipocine #Epilepsy_Treatment #LPCN_2101

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies Lipocine Inc. shares Q2 financial results and advancements on LPCN 1154, a treatment for postpartum depression, alongside updates on LPCN 2401.

Lipocine Reports Second Quarter Financial Results and Updates on Pivotal Studies #USA #Salt_Lake_City #Lipocine #LPCN_1154 #TLANDO

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 Join Lipocine's virtual R&D investor event on July 9, 2025, to explore LPCN 1154's potential in treating postpartum depression, alongside expert insights.

Lipocine's Virtual Investor Event on LPCN 1154 for Postpartum Depression Set for July 2025 #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's TLANDO® Submission Marks a New Era in TRT in Canada Lipocine Inc. announces a New Drug Submission for TLANDO® in Canada, aiming to meet the growing demand for testosterone replacement therapy.

Lipocine's TLANDO® Submission Marks a New Era in TRT in Canada #Canada #Salt_Lake_City #Lipocine #TLANDO #TRT

Lipocine's LPCN 1148 Gains Recognition in Hepatology Journal for Cirrhosis Treatment Lipocine's LPCN 1148 has been showcased in the Hepatology journal as a novel treatment targeting cirrhosis with significant implications for patients.

Lipocine's LPCN 1148 Gains Recognition in Hepatology Journal for Cirrhosis Treatment #United_States #Salt_Lake_City #Lipocine #LPCN_1148 #cirrhosis

Lipocine to Showcase Innovative Therapeutics at A.G.P.'s Annual Healthcare Event Lipocine Inc. will present its advanced drug delivery technology at A.G.P.'s Annual Healthcare Company Showcase on May 21, 2025, highlighting promising therapeutic candidates.

Lipocine to Showcase Innovative Therapeutics at A.G.P.'s Annual Healthcare Event #United_States #NASDAQ #Salt_Lake_City #Lipocine #TLANDO

Lipocine Expands Presence in Brazil with TLANDO® Licensing Agreement Lipocine Inc. announces a new licensing agreement with Aché for TLANDO®, a testosterone therapy, aimed at tapping into Brazil's growing market for prescription testosterone products.

Lipocine Expands Presence in Brazil with TLANDO® Licensing Agreement #Brazil #São_Paulo #Lipocine #TLANDO #Aché

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression Lipocine Inc. has launched a Phase 3 trial for LPCN 1154, aimed at treating postpartum depression through effective oral delivery.

Lipocine Begins Phase 3 Trial for LPCN 1154 to Treat Postpartum Depression #United_States #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

Lipocine's Exciting FDA Label Changes Enhance Testosterone Treatments Lipocine Inc. announces FDA labeling updates for testosterone products, enhancing safety and efficacy perceptions crucial for patient treatment.

Lipocine's Exciting FDA Label Changes Enhance Testosterone Treatments #United_States #FDA #Salt_Lake_City #Testosterone #Lipocine

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression Lipocine's latest regulatory guidance suggests further safety and efficacy trials for LPCN 1154, aiming to address postpartum depression in women rapidly.

Lipocine Advances Critical Regulatory Journey for LPCN 1154 in Treating Postpartum Depression #USA #Salt_Lake_City #Lipocine #LPCN_1154 #postpartum_depression

FDA Designates Lipocine's LPCN 1148 for Fast Track Treatment of Sarcopenia in Cirrhosis Patients Lipocine Inc. has received FDA Fast Track Designation for LPCN 1148, an innovative treatment targeting sarcopenia in decompensated cirrhosis patients.

FDA Designates Lipocine's LPCN 1148 for Fast Track Treatment of Sarcopenia in Cirrhosis Patients #United_States #Salt_Lake_City #Lipocine #LPCN_1148 #Sarcopenia